The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling

PLoS Medicine

Volumn 13, Issue 10, 2016, Pages

  Houben, Rein M G J ^a   Dodd, Peter J ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIAL TRANSMISSION; DISEASE COURSE; HUMAN; INFECTION RISK; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; SENSITIVITY ANALYSIS; TUBERCULIN TEST; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; DRUG EFFECTS; GLOBAL HEALTH; INCIDENCE; LATENT TUBERCULOSIS; MICROBIOLOGY; PHYSIOLOGY; RISK; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; GLOBAL HEALTH; HUMANS; INCIDENCE; ISONIAZID; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RISK; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84994259668     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002152     Document Type: Article

References (32)

1. World Health Organisation. Global Tuberculosis Report 2015. Geneva: 2015. http://www.who.int/tb/publications/global_report/en/ (Accessed 23 September 2016)
2. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB, Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis. 2002;185(3):401–4. doi: 10.1086/33834211807725.
3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC, Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA: the journal of the American Medical Association. 1999;282(7):677–86. Epub 1999/10/12. 10517722.
4. Getahun H, Matteelli A, Chaisson RE, Raviglione M, Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35. doi: 10.1056/NEJMra140542726017823.
5. World Health Organisation. Tuberculosis Fact Sheet 2015 [1st March 2016]. http://www.who.int/mediacentre/factsheets/fs104/en/
6. Centers for Disease Control (USA). Tuberculosis—Data and Statistics 2015 [1st March 2016]. http://www.cdc.gov/tb/statistics/default.htm.
7. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new End TB Strategy. Lancet. 2015;385:1799–801. doi: 10.1016/S0140-6736(15)60570-010.1016/S0140-6736(15)60570-0 Epub 2015 Mar 24. 25814376.
8. United Nations—Department of Economic and Social Affairs—Population Division. World Population Prospects: The 2015 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.241. 2015.
9. van Leth F, van der Werf MJ, Borgdorff MW, Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. Bull World Health Organ. 2008;86(1):20–6. Epub 2008/02/01. doi: 10.2471/blt.06.03780418235886; PubMed Central PMCID: PMC2647347.
10. Trunz BB, Fine P, Dye C, Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173–80. doi: 10.1016/S0140-6736(06)68507-316616560.
11. World Health OrganisationFramework towards TB elimination in low-incidence countries. Geneva: World Health Organisation, 2014. http://www.who.int/tb/publications/elimination_framework/en/ (Accessed 23 September 2016)
12. Esmail H, Barry CE, 3rdYoung DB, Wilkinson RJ, The ongoing challenge of latent tuberculosis. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2014;369(1645):20130437. Epub 2014/05/14. doi: 10.1098/rstb.2013.043724821923; PubMed Central PMCID: PMC4024230.
13. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. The Lancet. 2016. doi: 10.1016/S0140-6736(15)01316-127017310
14. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55. Epub 2011/08/19. doi: 10.1016/S1473-3099(11)70210-921846592.
15. Cauthen GM, Pio A, ten Dam HG, Annual risk of tuberculous infection. 1988. Bull World Health Organ. 2002;80(6):503–11; discussion 1–2. Epub 2002/07/20. 12132011; PubMed Central PMCID: PMC2567543.
16. Dodd PJ, Gardiner E, Coghlan R, Seddon JA, Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. The Lancet Global health. 2014;2(8):e453–9. doi: 10.1016/S2214-109X(14)70245-125103518.
17. Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, Marx FM, Jenkins HE, Cohen T, Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infect Dis. 2016;16(1):282. doi: 10.1186/s12879-016-1617-927296716; PubMed Central PMCID: PMCPMC4906576.
18. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163(9):1009–21. doi: 10.1001/archinte.163.9.100912742798.
19. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR, Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis. 2012;54(6):784–91. Epub 2012/01/24. doi: 10.1093/cid/cir95122267721; PubMed Central PMCID: PMC3284215.
20. Sutherland I, Svandova E, Radhakrishna S, The development of clinical tuberculosis following infection with tubercle bacilli. Tubercle. 1982;63(4):255–68. doi: 10.1016/s0041-3879(82)80013-56763793.
21. Vynnycky E, Fine PE, The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect. 1997;119(2):183–201. doi: 10.1017/s09502688970079179363017.
22. Dodd PJ, Sismanidis C, Seddon JA, Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. The Lancet Infectious Diseases. 2016. doi: 10.1016/S1473-3099(16)30132-3 PubMed Central PMCID: PMC27342768. 27342768
23. Ferebee SH, Mount FW, Murray FJ, Livesay VT, A Controlled Trial of Isoniazid Prophylaxis in Mental Institutions. The American review of respiratory disease. 1963;88:161–75. doi: 10.1164/arrd.1963.88.2.16114045220.
24. Sloot R, Schim van der Loeff MF, Kouw PM, Borgdorff MW, Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med. 2014;190(9):1044–52. doi: 10.1164/rccm.201406-1159OC25265362.
25. Mancuso JD, Diffenderfer JM, Ghassemieh BJ, Horne DJ, Kao TC, The Prevalence of Latent Tuberculosis Infection in the United States. Am J Respir Crit Care Med. 2016. Epub 2016/02/13. doi: 10.1164/rccm.201508-1683OC26866439.
26. Horsburgh CR, Jr.O'Donnell M, Chamblee S, Moreland JL, Johnson J, Marsh BJ, et al. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med. 2010;182(3):420–5. doi: 10.1164/rccm.200909-1355OC20395560; PubMed Central PMCID: PMC2921602.
27. United Nations. Sustainable Development Goals 2015 [17-April-2015]. https://sustainabledevelopment.un.org/topics/sustainabledevelopmentgoals.
28. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clinical microbiology reviews. 2014;27(1):3–20. doi: 10.1128/CMR.00034-1324396134; PubMed Central PMCID: PMC3910908.
29. World Health OrganisationGuidelines on the Management of Latent Tuberculosis Infection. Geneva: World Health Organization. Copyright (c) World Health Organization 2015., 2015. http://www.who.int/tb/publications/latent-tuberculosis-infection/en/ (Accessed on 23 September 2016)
30. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Jr.Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(33):13980–5. Epub 2009/08/12. 0901720106 [pii] doi: 10.1073/pnas.090172010619666590; PubMed Central PMCID: PMC2720405.
31. Janssens JP, Rieder HL, An ecological analysis of incidence of tuberculosis and per capita gross domestic product. Eur Respir J. 2008;32(5):1415–6. doi: 10.1183/09031936.0007870818978146.
32. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M, Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ. 2009;87(9):683–91. doi: 10.2471/blt.08.05845319784448; PubMed Central PMCID: PMCPMC2739916.